期刊文献+

原发性食管恶性黑色素瘤1例

下载PDF
导出
摘要 患者男,61岁。因进行吞咽困难1个月,于2013年10月7日入院。患者无声音嘶哑、饮水呛咳,无胸闷、憋气,无咳嗽、咳痰。查体:浅表淋巴结无肿大,全身皮肤黏膜无恶变倾向的色素痣、斑及类似原发病灶,心肺腹未见异常。钡餐示,食管中下段见3 cm×2.6 cm充盈缺损,管壁僵硬,黏膜中断、蠕动消失,考虑为食管癌。胃镜示,进镜30~35 cm食管管壁见黑褐色隆起型肿物,质硬、易出血(插页Ⅵ图18),活检提示恶性黑色素瘤。胸部、腹部CT示。
机构地区 山东省肿瘤医院
出处 《山东医药》 CAS 北大核心 2015年第20期110-110,116,共2页 Shandong Medical Journal
  • 相关文献

参考文献4

  • 1Shaohua Wang,Yuji Tachimori,Nobukazu Hokamura,Hiroyasu Igaki,Takayoshi Kishino,Ryoji Kushima.Diagnosis and Surgical Outcomes for Primary Malignant Melanoma of the Esophagus: A Single-Center Experience[J]. The Annals of Thoracic Surgery . 2013
  • 2Takeshi Nonoshita,Yoshiyuki Shioyama,Satoshi Nomoto,Saiji Ohga,Kayoko Ohnishi,Kazushige Atsumi,Kotaro Terashima,Shuji Matsuura,Katsumasa Nakamura,Hideki Hirata,Hiroshi Honda.Effective palliative radiotherapy in primary malignant melanoma of the esophagus: a case report. Cases Journal . 2009
  • 3Chang Fuju,Deere Harriet.Esophageal melanocytosis morphologic features and review of the literature. Archives of Pathology . 2006
  • 4郭军.恶性黑色素瘤治疗的新进展[J].临床肿瘤学杂志,2007,12(12):881-884. 被引量:25

二级参考文献27

  • 1Agop Y. Bcl-2 antisense ( oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group[ J ]. JCO, 2006, 24 (29) :4738 - 4745.
  • 2Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma [ J ]. Proc Natl Acad Sci U S A, 2003, 100:8372- 8377.
  • 3Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients[J]. Proc Natl Acad Sci U S A, 2003, 100:4712 -4717.
  • 4Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4 [ J]. J Clin Oncol, 2005, 23:6043 -6053.
  • 5Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase Ⅰ trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages Ⅲ and Ⅳ melanoma[J]. J Clin Oncol, 2005, 23:741 -750.
  • 6Ribas A, Camacho LH, I.opez-Berestein G, et al. Antitumor activity in melanoma and antiself responses in a phase Ⅰ trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 [ J ]. J Clin Oncol, 2005, 23:8968 - 8977.
  • 7Maker AV, Phan GQ, Attia P, et al. Tumor regression and auto- immunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase Ⅰ/Ⅱ study [J]. Ann Surg Oncol, 2005, 12:1005 -1016.
  • 8Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer[ J ]. J Immunother, 2005, 28 : 593-598.
  • 9Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage Ⅲ B melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses [ J ]. J Clin Oncol, 2006, 24:3164-3171.
  • 10Kirkwood JM, Strawderman MH, Emstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684[ J]. J Clin Oncol, 1996, 14(1 ):7- 17.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部